menu

Medical Program: Assessing Biosimilar Medications for Inflammatory Bowel Diseases

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Assessing Biosimilar Medications for Inflammatory Bowel Diseases

close
Assessing Biosimilar Medications for Inflammatory Bowel Diseases
Restart
Resume
Read full article
Choose a format
Media formats available:
A pre-test is required to view this content.
A pre-survey is required to view this content.
Details
Presenters
Comments
  • In Collaboration with

  • Overview

    Biosimilar medications have now entered the clinical landscape of treatment protocols for several disciplines—including gastroenterology. Joining Dr. Thomas Ullman to discuss the biosimilars that are available for Crohn’s disease and ulcerative colitis and how other parts of the world are using them are Dr. Sarah Yim, Acting Director of the Office of Therapeutic Biologics & Biosimilars, and Dr. Juli Tomaino, a pediatric gastroenterologist and Lead Medical Officer at the FDA.

  • Publish Date

    Release Date: 11/06/2019

Facebook Comments

Recommended
Details
Presenters
Comments
  • In Collaboration with

  • Overview

    Biosimilar medications have now entered the clinical landscape of treatment protocols for several disciplines—including gastroenterology. Joining Dr. Thomas Ullman to discuss the biosimilars that are available for Crohn’s disease and ulcerative colitis and how other parts of the world are using them are Dr. Sarah Yim, Acting Director of the Office of Therapeutic Biologics & Biosimilars, and Dr. Juli Tomaino, a pediatric gastroenterologist and Lead Medical Officer at the FDA.

  • Publish Date

    Release Date: 11/06/2019

Facebook Comments

Programs 8/2/21